EGFR and chronic myelogenous leukemia, BCR-ABL1 positive: CRKL, best known as a substrate of BCR-ABL kinase in chronic myelogenous leukemia (CML) with Philadelphia chromosome, has been described as an oncogene that is amplified in a subset of EGFR-inhibitor resistant NSCLCs [24, 29].